TechBio innovator: Brainomix case study


Brainomix.jpg 1

Brainomix's software is an award-winning imaging biomarker that uses mathematical algorithms to extract information from medical images, to enable precision medicine for better treatment decisions in stroke and lung fibrosis. BIA's latest TechBio 2023, the UK driving  AI revolution report case study explores how this software works, the opportunities and challenges. 

What does the company do?  


Brainomix specialises in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning imaging biomarkers and software solutions that are used in more than 30 countries worldwide.  


How does the technology work?  

Brainomix's flagship product, the 360 Stroke platform, is a collection of tools that use state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.  

A recent study found that the implementation of the 360 Stroke platform enabled faster treatment, reducing the door-in-door-out (DIDO) time by more than one hour from 140 to 79 minutes. More importantly, the study also found that the rate of patients achieving functional independence (mRS 0-2 @ 90 days) trebled, from 16% to 48%.  

As a result of an NHS AI grant that Brainominx were awarded in September 2020, they were able to deploy the 360 Stroke platform across five networks in the UK. Recent data collected by the Oxford Academic Health Science Network found that the sites that had adopted Brainomix 360 Stroke platform had a significantly higher rate of thrombectomy, a lifechanging treatment which can reduce disability and prevent or limit long-term care needs in patients with the most severe strokes. 

 How will it be used?  

The Brainomix 360 Stroke platform is seamlessly integrated into a stroke network, automatically processing any brain scans ordered as part of the stroke imaging protocol, and then generating AI-derived outputs that help a physician decide the best course of treatment. The Brainomix 360 platform is the most comprehensive stroke AI imaging platform, supporting all levels of imaging needs across the network.  

What are the opportunities and challenges?  

Brainomix's greatest opportunity in the near term is to expand its commercial operations into the US

Brainomix (1).png

market. They are currently market leaders in Europe, with some impressive recent milestones, including a national-level deployment of software across all 36 Hungarian stroke centres, as well as winning the Welsh national tender. Brainomix are looking to leverage this success and experience into the US market, which remains the most lucrative market globally, but with fierce competition from companies such as RapidAI and  

In terms of challenges, like all other AI companies, are facing growing scepticism – and, in some cases, even distress – about the role and value of AI, but Brainomix believe that there is growing real-world evidence to demonstrate the value of their technology in stroke. 



More news and updates 

The UK's genomics sector: Poised for continued growth and impact

Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.

CEO Update - 4 December 2023

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.

bioProcessUK 2023: Honouring excellence, unveiling future leaders 

In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.

CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.

Autumn Statement 2023 analysis

The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

Member spotlight: meet the Bio-Based and Biodegradable Industries Association

The Bio-Based and Biodegradable Industries Association (BBIA) and The BioIndustry Association (BIA) enter a mutual membership agreement to strengthen collaboration and support each other's work and member communities.

Bioprocessing: Unraveling the future by examining the past

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation.

CEO Update - 20 November 2023

London Life Sciences Week last week had an amazing buzz. I think there were more Americans in life science over for one week than I’ve ever experienced – centred on the Jefferies Healthcare Conference. At the same time, London was also full of Europeans at events like the Scrip Awards, where Jeremy Levin received the Lifetime Achievement Award and gave an impactful speech. The connectivity was immense - with a massive range of events that were really vibrant, diverse and inclusive.

London Life Sciences Week: connecting the global biotech community

London Life Sciences Week united the global biotech community for a dynamic week of networking and dealmaking. The BIA representatives were out and about throughout the week, networking with members and stakeholders. In this blog, Steve Bates OBE, CEO of BioIndustry Association, summarises insights based on the BIA team's first-hand experience.


More within